PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015707

GI

Evidence text

Paper-level observation

the enhanced frequency of splenic CD4+ (P < 0.0001), CD8+ (P < 0.0001), and CD8+ IL2+ T cells (P < 0.0249), and CD8+/Treg ratio (P < 0.0001) (Figure S14d–g) compared to the other treated groups.
textConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
<
Raw observation
P < 0.0001 vs other groups
Normalized measurement
<0.0001
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.